Hepatitis C – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hepatitis C – Pipeline Review, H2 2016’, provides an overview of the Hepatitis C pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis C

The report reviews pipeline therapeutics for Hepatitis C by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatitis C therapeutics and enlists all their major and minor projects

The report assesses Hepatitis C therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatitis C

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatitis C

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences, Inc.

AbbVie Inc

AIMM Therapeutics B.V.

Akshaya Bio Inc.

Amarillo Biosciences, Inc.

Amarna Therapeutics B.V.

ARA Healthcare Pvt. Ltd.

Aviragen Therapeutics, Inc.

Beijing Kawin Technology Share-Holding Co., Ltd.

Benitec Biopharma Limited

Beta Pharma, Inc.

Biogenomics Limited

BioLineRx, Ltd.

Bionor Pharma ASA

Biotest AG

Biotron Limited

Boehringer Ingelheim GmbH

Bolder Biotechnology, Inc.

Bristol-Myers Squibb Company

Chugai Pharmaceutical Co., Ltd.

Cocrystal Pharma, Inc.

Conatus Pharmaceuticals Inc.

ContraVir Pharmaceuticals, Inc.

DEKK-TEC, Inc.

Delpor, Inc.

Digna Biotech, S.L.

Enanta Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Formune S.L.

Genecode AS

GeneCure LLC

Gilead Sciences, Inc.

GinkgoPharma Co. Ltd.

GlaxoSmithKline Plc

HanAll Biopharma Co., Ltd.

HEC Pharm Co., Ltd.

ImmunoBiology Limited

Inovio Pharmaceuticals, Inc.

Integrated BioTherapeutics, Inc.

JN-International Medical Corporation

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kineta, Inc.

LG Life Science LTD.

Ligand Pharmaceuticals, Inc.

Medivir AB

Merck & Co., Inc.

Microbio Co., Ltd.

Microbiotix, Inc.

MultiCell Technologies, Inc.

NeuroVive Pharmaceutical AB

Novartis AG

NovaTarg Therapeutics, Inc

Ono Pharmaceutical Co., Ltd.

Pfenex Inc.

Pfizer Inc.

PharmaEssentia Corporation

Polaris Pharmaceuticals, Inc.

Presidio Pharmaceuticals, Inc.

Profectus BioSciences, Inc.

Regulus Therapeutics Inc.

REPLICor Inc.

Rodos BioTarget GmbH

Savoy Pharmaceuticals, Inc.

SomaGenics, Inc.

Sorrento Therapeutics, Inc.

Spring Bank Pharmaceuticals, Inc.

TaiGen Biotechnology Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd.

TGV-Laboratories

Therapix Biosciences Ltd.

Therapure Biopharma Inc.

Vakzine Projekt Management GmbH

Vertex Pharmaceuticals Incorporated

WhanIn Pharmaceutical Co., Ltd.

Zylacta Corporation

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Hepatitis C Overview 8

Therapeutics Development 9

Hepatitis C - Therapeutics under Development by Companies 11

Hepatitis C - Therapeutics under Investigation by Universities/Institutes 18

Hepatitis C - Pipeline Products Glance 21

Hepatitis C - Products under Development by Companies 25

Hepatitis C - Products under Investigation by Universities/Institutes 36

Hepatitis C - Companies Involved in Therapeutics Development 38

Hepatitis C - Therapeutics Assessment 114

Drug Profiles 134

Hepatitis C - Dormant Projects 454

Hepatitis C - Discontinued Products 482

Hepatitis C - Product Development Milestones 490

Appendix 501

List of Tables

List of Tables

Number of Products under Development for Hepatitis C, H2 2016 30

Number of Products under Development for Hepatitis C – Comparative Analysis, H2 2016 31

Number of Products under Development by Companies, H2 2016 33

Number of Products under Development by Companies, H2 2016 (Contd..1) 34

Number of Products under Development by Companies, H2 2016 (Contd..2) 35

Number of Products under Development by Companies, H2 2016 (Contd..3) 36

Number of Products under Development by Companies, H2 2016 (Contd..4) 37

Number of Products under Development by Companies, H2 2016 (Contd..5) 38

Number of Products under Investigation by Universities/Institutes, H2 2016 40

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 41

Comparative Analysis by Late Stage Development, H2 2016 42

Comparative Analysis by Clinical Stage Development, H2 2016 43

Comparative Analysis by Early Stage Development, H2 2016 44

Comparative Analysis by Unknown Stage Development, H2 2016 45

Products under Development by Companies, H2 2016 46

Products under Development by Companies, H2 2016 (Contd..1) 47

Products under Development by Companies, H2 2016 (Contd..2) 48

Products under Development by Companies, H2 2016 (Contd..3) 49

Products under Development by Companies, H2 2016 (Contd..4) 50

Products under Development by Companies, H2 2016 (Contd..5) 51

Products under Development by Companies, H2 2016 (Contd..6) 52

Products under Development by Companies, H2 2016 (Contd..7) 53

Products under Development by Companies, H2 2016 (Contd..8) 54

Products under Development by Companies, H2 2016 (Contd..9) 55

Products under Development by Companies, H2 2016 (Contd..10) 56

Products under Investigation by Universities/Institutes, H2 2016 57

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 58

Hepatitis C – Pipeline by 3-V Biosciences, Inc., H2 2016 59

Hepatitis C – Pipeline by AbbVie Inc, H2 2016 60

Hepatitis C – Pipeline by AIMM Therapeutics B.V., H2 2016 61

Hepatitis C – Pipeline by Akshaya Bio Inc., H2 2016 62

Hepatitis C – Pipeline by Amarillo Biosciences, Inc., H2 2016 63

Hepatitis C – Pipeline by Amarna Therapeutics B.V., H2 2016 64

Hepatitis C – Pipeline by ARA Healthcare Pvt. Ltd., H2 2016 65

Hepatitis C – Pipeline by Aviragen Therapeutics, Inc., H2 2016 66

Hepatitis C – Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016 67

Hepatitis C – Pipeline by Benitec Biopharma Limited, H2 2016 68

Hepatitis C – Pipeline by Beta Pharma, Inc., H2 2016 69

Hepatitis C – Pipeline by Biogenomics Limited, H2 2016 70

Hepatitis C – Pipeline by BioLineRx, Ltd., H2 2016 71

Hepatitis C – Pipeline by Bionor Pharma ASA, H2 2016 72

Hepatitis C – Pipeline by Biotest AG, H2 2016 73

Hepatitis C – Pipeline by Biotron Limited, H2 2016 74

Hepatitis C – Pipeline by Boehringer Ingelheim GmbH, H2 2016 75

Hepatitis C – Pipeline by Bolder Biotechnology, Inc., H2 2016 76

Hepatitis C – Pipeline by Bristol-Myers Squibb Company, H2 2016 77

Hepatitis C – Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 78

Hepatitis C – Pipeline by Cocrystal Pharma, Inc., H2 2016 79

Hepatitis C – Pipeline by Conatus Pharmaceuticals Inc., H2 2016 80

Hepatitis C – Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 81

Hepatitis C – Pipeline by DEKK-TEC, Inc., H2 2016 82

Hepatitis C – Pipeline by Delpor, Inc., H2 2016 83

Hepatitis C – Pipeline by Digna Biotech, S.L., H2 2016 84

Hepatitis C – Pipeline by Enanta Pharmaceuticals, Inc., H2 2016 85

Hepatitis C – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 86

Hepatitis C – Pipeline by Formune S.L., H2 2016 87

Hepatitis C – Pipeline by Genecode AS, H2 2016 88

Hepatitis C – Pipeline by GeneCure LLC, H2 2016 89

Hepatitis C – Pipeline by Gilead Sciences, Inc., H2 2016 90

Hepatitis C – Pipeline by GinkgoPharma Co. Ltd., H2 2016 91

Hepatitis C – Pipeline by GlaxoSmithKline Plc, H2 2016 92

Hepatitis C – Pipeline by HanAll Biopharma Co., Ltd., H2 2016 93

Hepatitis C – Pipeline by HEC Pharm Co., Ltd., H2 2016 94

Hepatitis C – Pipeline by ImmunoBiology Limited, H2 2016 95

Hepatitis C – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 96

Hepatitis C – Pipeline by Integrated BioTherapeutics, Inc., H2 2016 97

Hepatitis C – Pipeline by JN-International Medical Corporation, H2 2016 98

Hepatitis C – Pipeline by Johnson & Johnson, H2 2016 99

Hepatitis C – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 100

Hepatitis C – Pipeline by Kineta, Inc., H2 2016 101

Hepatitis C – Pipeline by LG Life Science LTD., H2 2016 102

Hepatitis C – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 103

Hepatitis C – Pipeline by Medivir AB, H2 2016 104

Hepatitis C – Pipeline by Merck & Co., Inc., H2 2016 105

Hepatitis C – Pipeline by Microbio Co., Ltd., H2 2016 106

Hepatitis C – Pipeline by Microbiotix, Inc., H2 2016 107

Hepatitis C – Pipeline by MultiCell Technologies, Inc., H2 2016 108

Hepatitis C – Pipeline by NeuroVive Pharmaceutical AB, H2 2016 109

Hepatitis C – Pipeline by Novartis AG, H2 2016 110

Hepatitis C – Pipeline by NovaTarg Therapeutics, Inc, H2 2016 111

Hepatitis C – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 112

Hepatitis C – Pipeline by Pfenex Inc., H2 2016 113

Hepatitis C – Pipeline by Pfizer Inc., H2 2016 114

Hepatitis C – Pipeline by PharmaEssentia Corporation, H2 2016 115

Hepatitis C – Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 116

Hepatitis C – Pipeline by Presidio Pharmaceuticals, Inc., H2 2016 117

Hepatitis C – Pipeline by Profectus BioSciences, Inc., H2 2016 118

Hepatitis C – Pipeline by Regulus Therapeutics Inc., H2 2016 119

Hepatitis C – Pipeline by REPLICor Inc., H2 2016 120

Hepatitis C – Pipeline by Rodos BioTarget GmbH, H2 2016 121

Hepatitis C – Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 122

Hepatitis C – Pipeline by SomaGenics, Inc., H2 2016 123

Hepatitis C – Pipeline by Sorrento Therapeutics, Inc., H2 2016 124

Hepatitis C – Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 125

Hepatitis C – Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 126

Hepatitis C – Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016 127

Hepatitis C – Pipeline by TGV-Laboratories, H2 2016 128

Hepatitis C – Pipeline by Therapix Biosciences Ltd., H2 2016 129

Hepatitis C – Pipeline by Therapure Biopharma Inc., H2 2016 130

Hepatitis C – Pipeline by Vakzine Projekt Management GmbH, H2 2016 131

Hepatitis C – Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 132

Hepatitis C – Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016 133

Hepatitis C – Pipeline by Zylacta Corporation, H2 2016 134

Assessment by Monotherapy Products, H2 2016 135

Assessment by Combination Products, H2 2016 136

Number of Products by Stage and Target, H2 2016 138

Number of Products by Stage and Mechanism of Action, H2 2016 145

Number of Products by Stage and Route of Administration, H2 2016 152

Number of Products by Stage and Molecule Type, H2 2016 154

Hepatitis C – Dormant Projects, H2 2016 475

Hepatitis C – Dormant Projects (Contd..1), H2 2016 476

Hepatitis C – Dormant Projects (Contd..2), H2 2016 477

Hepatitis C – Dormant Projects (Contd..3), H2 2016 478

Hepatitis C – Dormant Projects (Contd..4), H2 2016 479

Hepatitis C – Dormant Projects (Contd..5), H2 2016 480

Hepatitis C – Dormant Projects (Contd..6), H2 2016 481

Hepatitis C – Dormant Projects (Contd..7), H2 2016 482

Hepatitis C – Dormant Projects (Contd..8), H2 2016 483

Hepatitis C – Dormant Projects (Contd..9), H2 2016 484

Hepatitis C – Dormant Projects (Contd..10), H2 2016 485

Hepatitis C – Dormant Projects (Contd..11), H2 2016 486

Hepatitis C – Dormant Projects (Contd..12), H2 2016 487

Hepatitis C – Dormant Projects (Contd..13), H2 2016 488

Hepatitis C – Dormant Projects (Contd..14), H2 2016 489

Hepatitis C – Dormant Projects (Contd..15), H2 2016 490

Hepatitis C – Dormant Projects (Contd..16), H2 2016 491

Hepatitis C – Dormant Projects (Contd..17), H2 2016 492

Hepatitis C – Dormant Projects (Contd..18), H2 2016 493

Hepatitis C – Dormant Projects (Contd..19), H2 2016 494

Hepatitis C – Dormant Projects (Contd..20), H2 2016 495

Hepatitis C – Dormant Projects (Contd..21), H2 2016 496

Hepatitis C – Dormant Projects (Contd..22), H2 2016 497

Hepatitis C – Dormant Projects (Contd..23), H2 2016 498

Hepatitis C – Dormant Projects (Contd..24), H2 2016 499

Hepatitis C – Dormant Projects (Contd..25), H2 2016 500

Hepatitis C – Dormant Projects (Contd..26), H2 2016 501

Hepatitis C – Dormant Projects (Contd..27), H2 2016 502

Hepatitis C – Discontinued Products, H2 2016 503

Hepatitis C – Discontinued Products (Contd..1), H2 2016 504

Hepatitis C – Discontinued Products (Contd..2), H2 2016 505

Hepatitis C – Discontinued Products (Contd..3), H2 2016 506

Hepatitis C – Discontinued Products (Contd..4), H2 2016 507

Hepatitis C – Discontinued Products (Contd..5), H2 2016 508

Hepatitis C – Discontinued Products (Contd..6), H2 2016 509

Hepatitis C – Discontinued Products (Contd..7), H2 2016 510

List of Figures

List of Figures

Number of Products under Development for Hepatitis C, H2 2016 30

Number of Products under Development for Hepatitis C – Comparative Analysis, H2 2016 31

Number of Products under Development by Companies, H2 2016 32

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Comparative Analysis by Late Stage Development, H2 2016 42

Comparative Analysis by Clinical Stage Development, H2 2016 43

Comparative Analysis by Early Stage Products, H2 2016 44

Assessment by Monotherapy Products, H2 2016 135

Assessment by Combination Products, H2 2016 136

Number of Products by Top 10 Targets, H2 2016 137

Number of Products by Stage and Top 10 Targets, H2 2016 137

Number of Products by Top 10 Mechanism of Actions, H2 2016 144

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 144

Number of Products by Routes of Administration, H2 2016 151

Number of Products by Stage and Routes of Administration, H2 2016 151

Number of Products by Top 10 Molecule Types, H2 2016 153

Number of Products by Stage and Top 10 Molecule Types, H2 2016 153

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports